Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.10
CELG's Cash to Debt is ranked higher than
55% of the 1438 Companies
in the Global Biotechnology industry.

( Industry Median: 51.73 vs. CELG: 1.10 )
CELG' s 10-Year Cash to Debt Range
Min: 0.06   Max: No Debt
Current: 1.1

Equity to Asset 0.38
CELG's Equity to Asset is ranked higher than
57% of the 1086 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CELG: 0.38 )
CELG' s 10-Year Equity to Asset Range
Min: -0.3   Max: 0.88
Current: 0.38

-0.3
0.88
Interest Coverage 14.30
CELG's Interest Coverage is ranked lower than
51% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CELG: 14.30 )
CELG' s 10-Year Interest Coverage Range
Min: 4.47   Max: 428.04
Current: 14.3

4.47
428.04
F-Score: 8
Z-Score: 7.17
M-Score: -2.59
WACC vs ROIC
14.86%
41.19%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 32.84
CELG's Operating margin (%) is ranked higher than
97% of the 1163 Companies
in the Global Biotechnology industry.

( Industry Median: -91.29 vs. CELG: 32.84 )
CELG' s 10-Year Operating margin (%) Range
Min: -2309.09   Max: 32.84
Current: 32.84

-2309.09
32.84
Net-margin (%) 26.07
CELG's Net-margin (%) is ranked higher than
95% of the 1163 Companies
in the Global Biotechnology industry.

( Industry Median: -76.91 vs. CELG: 26.07 )
CELG' s 10-Year Net-margin (%) Range
Min: -2309.09   Max: 28.88
Current: 26.07

-2309.09
28.88
ROE (%) 36.74
CELG's ROE (%) is ranked higher than
98% of the 1318 Companies
in the Global Biotechnology industry.

( Industry Median: -31.17 vs. CELG: 36.74 )
CELG' s 10-Year ROE (%) Range
Min: -425.42   Max: 33.02
Current: 36.74

-425.42
33.02
ROA (%) 13.26
CELG's ROA (%) is ranked higher than
95% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -25.65 vs. CELG: 13.26 )
CELG' s 10-Year ROA (%) Range
Min: -166.78   Max: 15.8
Current: 13.26

-166.78
15.8
ROC (Joel Greenblatt) (%) 219.73
CELG's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 1405 Companies
in the Global Biotechnology industry.

( Industry Median: -346.25 vs. CELG: 219.73 )
CELG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1378.72   Max: 213.62
Current: 219.73

-1378.72
213.62
Revenue Growth (3Y)(%) 20.60
CELG's Revenue Growth (3Y)(%) is ranked higher than
88% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: 2.50 vs. CELG: 20.60 )
CELG' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 166.8
Current: 20.6

0
166.8
EBITDA Growth (3Y)(%) 20.40
CELG's EBITDA Growth (3Y)(%) is ranked higher than
88% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. CELG: 20.40 )
CELG' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 75.6
Current: 20.4

0
75.6
EPS Growth (3Y)(%) 19.00
CELG's EPS Growth (3Y)(%) is ranked higher than
88% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. CELG: 19.00 )
CELG' s 10-Year EPS Growth (3Y)(%) Range
Min: -63.2   Max: 118.1
Current: 19

-63.2
118.1
» CELG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

CELG Guru Trades in Q1 2014

John Burbank 1,670 sh (New)
Ken Fisher 37,321 sh (+1591.80%)
Ray Dalio 71,200 sh (+962.69%)
Louis Moore Bacon 42,614 sh (+752.28%)
Steven Cohen 71,089 sh (+276.79%)
Paul Tudor Jones 6,686 sh (+178.35%)
Jim Simons 1,606,830 sh (+14.33%)
Ronald Muhlenkamp 149,325 sh (+1.29%)
Pioneer Investments 1,552,050 sh (+0.95%)
John Keeley Sold Out
Mario Gabelli 10,770 sh (-3.58%)
RS Investment Management 40,572 sh (-4.15%)
Chuck Royce 600 sh (-33.33%)
Jeremy Grantham 34,100 sh (-60.77%)
» More
Q2 2014

CELG Guru Trades in Q2 2014

Joel Greenblatt 63,980 sh (New)
George Soros 688,000 sh (New)
Stanley Druckenmiller 276,000 sh (New)
Ken Fisher 131,064 sh (+75.59%)
Mario Gabelli 23,120 sh (+7.34%)
Steven Cohen 204,200 sh (unchged)
Paul Tudor Jones Sold Out
John Burbank Sold Out
Louis Moore Bacon Sold Out
Ray Dalio Sold Out
Chuck Royce Sold Out
Pioneer Investments 3,052,643 sh (-1.66%)
RS Investment Management 75,104 sh (-7.44%)
Jeremy Grantham 50,000 sh (-26.69%)
Ronald Muhlenkamp 144,140 sh (-51.74%)
Jim Simons 495,900 sh (-84.57%)
» More
Q3 2014

CELG Guru Trades in Q3 2014

Louis Moore Bacon 55,000 sh (New)
John Hussman 25,000 sh (New)
Stanley Druckenmiller 560,600 sh (+103.12%)
Ken Fisher 232,137 sh (+77.12%)
RS Investment Management 86,904 sh (+15.71%)
Mario Gabelli 25,760 sh (+11.42%)
Ronald Muhlenkamp 146,940 sh (+1.94%)
Pioneer Investments 3,080,374 sh (unchged)
Steven Cohen Sold Out
George Soros Sold Out
Joel Greenblatt Sold Out
Jeremy Grantham Sold Out
Jim Simons 30,400 sh (-93.87%)
» More
Q4 2014

CELG Guru Trades in Q4 2014

Paul Tudor Jones 3,776 sh (New)
Steven Cohen 110,400 sh (New)
Joel Greenblatt 10,259 sh (New)
Pioneer Investments 3,376,570 sh (+9.62%)
Louis Moore Bacon Sold Out
John Hussman Sold Out
Jim Simons Sold Out
Ken Fisher 227,331 sh (-2.07%)
Mario Gabelli 24,960 sh (-3.11%)
RS Investment Management 76,482 sh (-11.99%)
Stanley Druckenmiller 434,100 sh (-22.57%)
Ronald Muhlenkamp 86,240 sh (-41.31%)
» More
» Details

Insider Trades

Latest Guru Trades with CELG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 47.50
CELG's P/E(ttm) is ranked higher than
91% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 47.50 )
CELG' s 10-Year P/E(ttm) Range
Min: 17.91   Max: 618.59
Current: 47.5

17.91
618.59
Forward P/E 17.95
CELG's Forward P/E is ranked higher than
92% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 17.95 )
N/A
PE(NRI) 48.50
CELG's PE(NRI) is ranked higher than
93% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 48.50 )
CELG' s 10-Year PE(NRI) Range
Min: 17.81   Max: 482.5
Current: 48.5

17.81
482.5
P/B 13.80
CELG's P/B is ranked lower than
54% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. CELG: 13.80 )
CELG' s 10-Year P/B Range
Min: 4.02   Max: 23.45
Current: 13.8

4.02
23.45
P/S 12.37
CELG's P/S is ranked higher than
69% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 37.00 vs. CELG: 12.37 )
CELG' s 10-Year P/S Range
Min: 5.37   Max: 28.35
Current: 12.37

5.37
28.35
PFCF 36.00
CELG's PFCF is ranked higher than
94% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 36.00 )
CELG' s 10-Year PFCF Range
Min: 14.96   Max: 2925.5
Current: 36

14.96
2925.5
POCF 34.65
CELG's POCF is ranked higher than
93% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 34.65 )
CELG' s 10-Year POCF Range
Min: 13.82   Max: 937.83
Current: 34.65

13.82
937.83
EV-to-EBIT 36.17
CELG's EV-to-EBIT is ranked higher than
94% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 36.17 )
CELG' s 10-Year EV-to-EBIT Range
Min: -26.2   Max: 306.1
Current: 36.17

-26.2
306.1
PEG 2.10
CELG's PEG is ranked higher than
98% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 2.10 )
CELG' s 10-Year PEG Range
Min: 1.38   Max: 2.92
Current: 2.1

1.38
2.92
Shiller P/E 74.10
CELG's Shiller P/E is ranked higher than
93% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 74.10 )
CELG' s 10-Year Shiller P/E Range
Min: 56.57   Max: 2211
Current: 74.1

56.57
2211
Current Ratio 4.60
CELG's Current Ratio is ranked higher than
73% of the 1401 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. CELG: 4.60 )
CELG' s 10-Year Current Ratio Range
Min: 1.35   Max: 11.23
Current: 4.6

1.35
11.23
Quick Ratio 4.41
CELG's Quick Ratio is ranked higher than
74% of the 1401 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. CELG: 4.41 )
CELG' s 10-Year Quick Ratio Range
Min: 1.13   Max: 11.11
Current: 4.41

1.13
11.11
Days Inventory 343.02
CELG's Days Inventory is ranked higher than
78% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 343.02 )
CELG' s 10-Year Days Inventory Range
Min: 49.98   Max: 584
Current: 343.02

49.98
584
Days Sales Outstanding 55.52
CELG's Days Sales Outstanding is ranked higher than
85% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 139.31 vs. CELG: 55.52 )
CELG' s 10-Year Days Sales Outstanding Range
Min: 42.33   Max: 464.55
Current: 55.52

42.33
464.55

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 343.80
CELG's Price/Tangible Book is ranked lower than
66% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 10.60 vs. CELG: 343.80 )
CELG' s 10-Year Price/Tangible Book Range
Min: 6.24   Max: 338.97
Current: 343.8

6.24
338.97
Price/DCF (Projected) 3.10
CELG's Price/DCF (Projected) is ranked higher than
96% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 3.10 )
CELG' s 10-Year Price/DCF (Projected) Range
Min: 1.77   Max: 40.07
Current: 3.1

1.77
40.07
Price/Median PS Value 1.10
CELG's Price/Median PS Value is ranked higher than
85% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. CELG: 1.10 )
CELG' s 10-Year Price/Median PS Value Range
Min: 0.58   Max: 6.78
Current: 1.1

0.58
6.78
Price/Peter Lynch Fair Value 2.30
CELG's Price/Peter Lynch Fair Value is ranked higher than
97% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 2.30 )
CELG' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.46   Max: 5.1
Current: 2.3

0.46
5.1
Price/Graham Number 26.20
CELG's Price/Graham Number is ranked higher than
86% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CELG: 26.20 )
CELG' s 10-Year Price/Graham Number Range
Min: 3.29   Max: 25.83
Current: 26.2

3.29
25.83
Earnings Yield (Greenblatt) 2.80
CELG's Earnings Yield (Greenblatt) is ranked higher than
91% of the 1393 Companies
in the Global Biotechnology industry.

( Industry Median: -5.90 vs. CELG: 2.80 )
CELG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 6.6
Current: 2.8

0.3
6.6
Forward Rate of Return (Yacktman) 22.39
CELG's Forward Rate of Return (Yacktman) is ranked higher than
85% of the 178 Companies
in the Global Biotechnology industry.

( Industry Median: 15.60 vs. CELG: 22.39 )
CELG' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.4   Max: 34.8
Current: 22.39

-0.4
34.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CMXHY » details
Traded in other countries:CG3.Germany, CELG.Mexico, CELG.Switzerland,
Celgene Corp is incorporated in Delaware. The Company is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of new therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in new research and development designed to bring new therapies to market and we are involved in research in several scientific areas that may deliver proprietary next-generation therapies, targeting areas including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The Company' commercial stage products include REVLIMID(r), VIDAZA(r), ABRAXANE(r), POMALYST(r)/IMNOVID(r), THALOMID(r) (inclusive of Thalidomide CelgeneTM), ISTODAX(r) and azacitidine for injection (generic version of VIDAZA(r)). The Company faces competition from Amgen, AstraZeneca, Bristol-Myers-Squibb, Eisai, Gilead, Johnson & Johnson, Novartis, Pharmacyclics, Roche/Genentech, Sanofi and Takeda, AbbVie, Amgen, Biogen Idec, Eisai, Johnson & Johnson, Merck, Pfizer and UCB S.A. Regulation by governmental authorities in the United States and other countries is a significant factor in the manufacture and marketing of pharmaceuticals and in its ongoing research and development activities.
» More Articles for CELG

Headlines

Articles On GuruFocus.com
February Pick Of Biotech Stocks Feb 17 2015 
Celleration Acquisition Just the Start of Alliqua’s M&A Strategy Feb 04 2015 
J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Nov 18 2014 
Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Coun Nov 17 2014 
Three Attractively Priced Small Cap Biotech Stocks Nov 05 2014 
Weekly 52-Week Highs Highlight: ALL, SRE, CLX, CELG Oct 06 2014 
Ken Fisher's Top Increases of the First Quarter Apr 22 2014 
David Winters' 2013 Letter to Wintergreen Fund Shareholders Mar 05 2014 
You Can No Longer Ignore Biotech Feb 07 2014 

More From Our Partners
Why Goldman Sachs Is Wrong About These 3 Stocks - Analyst Blog Apr 15 2015 - ZACKS

More From Other Websites
How To Invest In ETFs: Tips To Trade Top Market Trends Apr 17 2015
Midday Glance: Biotechnology companies Apr 17 2015
Midday Glance: Biotechnology companies Apr 17 2015
Early Glance: Biotechnology companies Apr 17 2015
Early Glance: Biotechnology companies Apr 17 2015
Biotech giants present new data Apr 16 2015
Phase II Data for Apremilast in Behçet's Disease Published in The New England Journal of Medicine Apr 15 2015
Phase II Data for Apremilast in Behçet’s Disease Published in The New England Journal of Medicine Apr 15 2015
CELGENE CORP /DE/ Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Apr 15 2015
Celgene Corporation Elects Mr. Michael W. Bonney to Its Board of Directors Apr 15 2015
Celgene Corporation Elects Mr. Michael W. Bonney to Its Board of Directors Apr 15 2015
Five companies that may be looking to buy Ariad Pharmaceuticals Apr 14 2015
So You Want to Be a Short Seller… Apr 14 2015
Can a Small New Stem Cell Pact Move the Needle for Celgene? Apr 13 2015
Bullish earnings play in Celgene Apr 13 2015
Market's Moment of Truth: Brace for Earnings Apr 13 2015
Short Sellers Increase Their Bets Against Biotech Stocks Apr 13 2015
China equities at 7-year highs; Tokyo struggles to cross 20000 mark Apr 13 2015
Mesoblast Jumps Most in 4 Years as Celgene Invests $45 Million Apr 12 2015
Celgene And Mesoblast Enter Into Agreement Apr 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK